Matinas Biopharma Holdings, Inc. MTNB

Matinas BioPharma Holdings received a notice of non-compliance with NYSE American continued listing standards. Non-compliance notice creates delisting risk that can reduce liquidity and damage investor confidence.

Matinas BioPharma enters business combination with GH Power to form publicly traded clean energy and green hydrogen company; signs agreement to sell LNC platform and MAT2203 to Azurity Pharmaceuticals. Full pivot from biotech platform to unrelated clean energy sector via sale and combination redefines entire company trajectory.

GH Power will go public through a business combination with Matinas BioPharma Holdings, Inc. (MTNB). Business combination with GH Power marks a major strategic move for Matinas BioPharma.

Matinas BioPharma Holdings, Inc. (MTNB) received a notice of non-compliance with NYSE American continued listing standards. Non-compliance notice risks delisting, significantly eroding investor confidence and stock liquidity.

Matinas BioPharma Holdings, Inc. prices $10 million registered direct offering. The offering of $10 million is a significant move that can impact the company's financial performance and strategic positioning.

Matinas Biopharma Holdings, Inc. is undergoing a restructuring process to address ongoing challenges, with a renewed focus on its oral antifungal product MAT2203. The company aims to streamline operations and enhance its market position amid these difficulties. The restructuring and focus on MAT2203 could significantly impact the company's future performance and market positioning.

Matinas BioPharma Holdings, Inc. appointed Keith Murphy and Edward Neugeboren as independent members of its Board of Directors on March 11, 2025. Murphy will chair the Nominating and Governance Committee, while Neugeboren will chair the Compensation Committee. Both bring extensive biotech experience, with Murphy previously leading Organovo and Neugeboren having over 33 years in healthcare operations and investment banking. The appointments follow the departure of Matthew Wikler and Natasha Giordano from the Board. Matinas BioPharma focuses on innovative therapies using its lipid nanocrystal platform, including MAT2203, an oral treatment for invasive fungal infections. The appointments of experienced leaders to the Board are likely to significantly influence the company's strategic direction and market positioning.

Matinas BioPharma Holdings, Inc. announced a securities purchase agreement with investors for 3,300 shares of Series C Convertible Preferred Stock and warrants, generating $3.3 million in gross proceeds. The initial closing occurred on February 13, 2025, with a second closing contingent on shareholder approval. The funds will support general corporate purposes, particularly for MAT2203, an antifungal drug candidate. Dr. Robin L. Smith has been appointed to the Board of Directors, while Herbert J. Conrad has resigned. The company aims to reduce operating costs and explore strategic alternatives. The acquisition of preferred stock and the appointment of a highly experienced board member are significant strategic moves that could enhance the company's future performance.

Matinas BioPharma Holdings, Inc. appointed Evelyn D’An as an independent director and Chair of the Audit Committee, effective February 5, 2025. D’An brings extensive experience in corporate governance and financial oversight, having served as Chair of Audit Committees for various companies and as a former partner at Ernst & Young. CEO Jerome D. Jabbour expressed confidence that her expertise will enhance the board's capabilities during a crucial time for the company. The appointment of an experienced Audit Committee chair may moderately influence the company's governance and financial oversight.

Matinas BioPharma terminates partnership negotiations for MAT2203, implements 80% workforce reduction, and considers asset sale or dissolution. Termination of partnership negotiations, significant workforce reduction, and potential asset sale or dissolution could fundamentally alter the company's trajectory and investor sentiment.

Matinas BioPharma Holdings, Inc. signs non-binding term sheet for global rights to develop and commercialize oral MAT2203 for invasive aspergillosis. 31 patients enrolled in Compassionate/Expanded Use Access Program. Additional LNC platform work in inflammation and oncology completed. Signing global licensing rights for MAT2203 and positive clinical impact expected to significantly alter company's trajectory and investor sentiment.

Matinas BioPharma Holdings, Inc. will report second quarter 2024 financial results and provide a business update on August 14, 2024. The financial results and business update may moderately influence key areas such as financial performance and competitive positioning.

Matinas BioPharma successfully treated a patient with a limb-threatening mucor infection using its oral MAT2203 Compassionate/Expanded Use Access Program. Successful treatment of severe infection and positive clinical impact of MAT2203 could significantly impact future product development and market performance.

MAT2203, an oral antifungal treatment by Matinas BioPharma, will be discussed in a fireside chat with antifungal expert Dr. David Perlin on June 18th. The discussion on MAT2203's advantages and market potential with an antifungal expert could significantly impact Matinas Biopharma's future product development and market performance.

Matinas BioPharma presented new in vitro data at TIDES USA 2024 showing LNC platform delivering small oligonucleotides. The in vitro data demonstrating successful delivery of small oligonucleotides using LNCs could have a significant impact on Matinas BioPharma's future drug development and market performance.

Matinas BioPharma Holdings Inc provides update on MAT2203 progress and LNC platform programs, raises funds, and reports financial results for Q1 2024. Significant impact expected on future performance due to progress in key programs, potential partnerships, and financial stability.

Matinas BioPharma Holdings, Inc. provided updates on their MAT2203 program and other LNC platform initiatives, as well as financial results for Q1 2024. Significant impact expected on future performance due to progress in key programs and potential partnerships for MAT2203.

Matinas BioPharma reports Q1 2024 financial results and updates on MAT2203 development and LNC platform expansion. Significant impact expected on future development and market performance due to progress in MAT2203 program and LNC platform expansion.

Matinas BioPharma presents data on LNC platform for small oligonucleotide delivery at ASGCT Annual Meeting. The presentation of successful in vivo oral delivery of therapeutic oligonucleotides with the LNC platform could have a significant impact on Matinas Biopharma's future product development and market performance.

Matinas BioPharma to report Q1 2024 financial results and business update on May 9, 2024. The announcement of financial results and business update can significantly impact the company's future performance and market sentiment.

MAT2203, Matinas BioPharma's oral formulation of amphotericin B, shows efficacy in treating pulmonary mucormycosis in mice. The successful results of MAT2203 in treating mucormycosis infections could have a significant impact on Matinas Biopharma's future product development and market performance.

Matinas BioPharma Holdings, Inc. reached agreement with FDA on Phase III trial design for MAT2203 in patients with invasive aspergillosis. Company also reported progress in expanding LNC platform into oncology and inflammation. Significant impact expected on company's future with potential for major strategic moves and product launches.

Matinas BioPharma Holdings Inc announces progress on Phase 3 trial for MAT2203 and expansion of LNC platform into oncology and inflammation. Significant impact expected on company's future with potential for transformative technologies and strategic partnerships.

Matinas BioPharma reports 2023 financial results and provides business update. Agreement with FDA on Phase 3 trial, successful Compassionate/Expanded Use Program, and advancements in LNC platform indicate significant impact on future and market performance.

Matinas BioPharma announces positive safety data for oral LNC-Docetaxel formulation. The positive safety data for the oral LNC-Docetaxel formulation could lead to significant advancements in oncology applications and potentially redefine the company's competitive position.

Matinas BioPharma announced complete clinical response in three patients with invasive fusarium infection following treatment with MAT2203, leading to stock trading higher on Friday. The successful treatment outcomes in patients with limited options add to confidence for upcoming Phase 3 trial, potentially impacting future performance significantly.

Three patients with invasive fusarium infection achieve complete clinical response following treatment with MAT2203. The successful treatment outcomes and potential of MAT2203 to address unmet medical needs in invasive fungal infections could significantly impact Matinas Biopharma Holdings, Inc.'s future and market performance.

Matinas BioPharma reports positive outcomes in MAT2203 Compassionate/Expanded Use Access Program for patients with invasive fungal infections. The successful outcomes of MAT2203 in treating serious fungal infections could significantly impact the company's future product development and market performance.

Matinas BioPharma reaches agreement with FDA for Phase 3 trial of MAT2203 for invasive aspergillosis treatment. Phase 3 trial agreement with FDA for MAT2203 has significant potential impact on future market performance.

Matinas BioPharma CEO to present at Biotech Showcase 2024. Presentation at showcase could have a significant impact on future market performance and strategic moves.